144 related articles for article (PubMed ID: 30203935)
1. Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies.
Jiang Z; Zhao Y; Tian Y
Minerva Urol Nefrol; 2019 Aug; 71(4):373-380. PubMed ID: 30203935
[TBL] [Abstract][Full Text] [Related]
2. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer.
Hu B; Yang H; Yang H
Tumour Biol; 2014 Sep; 35(9):8573-80. PubMed ID: 24863945
[TBL] [Abstract][Full Text] [Related]
4. Progensa™ PCA3 test for prostate cancer.
Durand X; Moutereau S; Xylinas E; de la Taille A
Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
Bollito E; De Luca S; Cicilano M; Passera R; Grande S; Maccagnano C; Cappia S; Milillo A; Montorsi F; Scarpa RM; Papotti M; Randone DF
Anal Quant Cytol Histol; 2012 Apr; 34(2):96-104. PubMed ID: 22611765
[TBL] [Abstract][Full Text] [Related]
6. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
7. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
9. Age-Adapted Prostate Cancer Gene 3 Score Interpretation - Suggestions for Clinical Use.
Hennenlotter J; Neumann T; Alperowitz S; Wagner V; Hohneder A; Bedke J; Stenzl A; Todenhöfer T; Rausch S
Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162868
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: a meta-analysis.
Xue WJ; Ying XL; Jiang JH; Xu YH
J Cancer Res Ther; 2014 Nov; 10 Suppl():C218-21. PubMed ID: 25450286
[TBL] [Abstract][Full Text] [Related]
11. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
12. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.
Cui Y; Cao W; Li Q; Shen H; Liu C; Deng J; Xu J; Shao Q
Sci Rep; 2016 May; 6():25776. PubMed ID: 27161545
[TBL] [Abstract][Full Text] [Related]
14. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
[TBL] [Abstract][Full Text] [Related]
15. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
16. Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture.
Zheng K; Dou Y; He L; Li H; Zhang Z; Chen Y; Ye A; Liu W; Kong L
Oncol Rep; 2015 Nov; 34(5):2439-44. PubMed ID: 26351770
[TBL] [Abstract][Full Text] [Related]
17. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis.
Luo Y; Gou X; Huang P; Mou C
Asian J Androl; 2014; 16(3):487-92. PubMed ID: 24713827
[TBL] [Abstract][Full Text] [Related]
18. Molecular PCA3 diagnostics on prostatic fluid.
van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
[TBL] [Abstract][Full Text] [Related]
19. PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals.
Capoluongo E; Zambon CF; Basso D; Boccia S; Rocchetti S; Leoncini E; Palumbo S; Padoan A; Albino G; Todaro A; Prayer-Galetti T; Zattoni F; Zuppi C; Plebani M
Clin Chim Acta; 2014 Feb; 429():46-50. PubMed ID: 24269853
[TBL] [Abstract][Full Text] [Related]
20. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]